168 related articles for article (PubMed ID: 10632686)
1. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens.
Gilbert S; McBurney E
Dermatol Surg; 2000 Jan; 26(1):50-4. PubMed ID: 10632686
[TBL] [Abstract][Full Text] [Related]
2. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing.
Beeson WH; Rachel JD
Dermatol Surg; 2002 Apr; 28(4):331-6. PubMed ID: 11966791
[TBL] [Abstract][Full Text] [Related]
3. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing.
Alster TS; Nanni CA
Dermatol Surg; 1999 Mar; 25(3):242-6. PubMed ID: 10193975
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.
Dignani MC; Mykietiuk A; Michelet M; Intile D; Mammana L; Desmery P; Milone G; Pavlovsky S
Bone Marrow Transplant; 2002 Feb; 29(3):263-7. PubMed ID: 11859400
[TBL] [Abstract][Full Text] [Related]
5. Delayed reactivation of herpes simplex virus infection after facial laser resurfacing.
Johnson PJ; Hollins RR
Plast Reconstr Surg; 2000 Sep; 106(3):743-4. PubMed ID: 10987501
[No Abstract] [Full Text] [Related]
6. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
Warkentin DI; Epstein JB; Campbell LM; Yip JG; Cox VC; Ransier A; Barnett MJ; Marra F
Ann Pharmacother; 2002 Oct; 36(10):1525-31. PubMed ID: 12243600
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures.
Miller CS; Cunningham LL; Lindroth JE; Avdiushko SA
J Am Dent Assoc; 2004 Sep; 135(9):1311-8. PubMed ID: 15493396
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
9. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia.
Orlowski RZ; Mills SR; Hartley EE; Ye X; Piantadosi S; Ambinder RF; Gore SD; Miller CB
Leuk Lymphoma; 2004 Nov; 45(11):2215-9. PubMed ID: 15512809
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of valacyclovir in preventing reactivation of herpes gladiatorum in wrestlers.
Anderson BJ
Clin J Sport Med; 1999 Apr; 9(2):86-90. PubMed ID: 10442623
[TBL] [Abstract][Full Text] [Related]
11. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
12. Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.
Asbell PA
Trans Am Ophthalmol Soc; 2000; 98():285-303. PubMed ID: 11190029
[TBL] [Abstract][Full Text] [Related]
13. Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.
Liesveld JL; Abboud CN; Ifthikharuddin JJ; Lancet JE; Wedow LA; Oliva J; Stamm CG; Nichols D
Biol Blood Marrow Transplant; 2002; 8(12):662-5. PubMed ID: 12523578
[TBL] [Abstract][Full Text] [Related]
14. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
[TBL] [Abstract][Full Text] [Related]
15. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Valacyclovir to Prevent Outbreaks of Primary Herpes Gladiatorum at a 28-Day Wrestling Camp: A 10-Year Review.
Anderson BJ; McGuire DP; Reed M; Foster M; Ortiz D
Clin J Sport Med; 2016 Jul; 26(4):272-8. PubMed ID: 26540599
[TBL] [Abstract][Full Text] [Related]
17. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
18. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
19. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Sheffield JS; Hill JB; Hollier LM; Laibl VR; Roberts SW; Sanchez PJ; Wendel GD
Obstet Gynecol; 2006 Jul; 108(1):141-7. PubMed ID: 16816068
[TBL] [Abstract][Full Text] [Related]
20. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
